Normalised EBITDA margin and NEPS are expected to improve 6%–10% year-over-year, with revenue up 2.2%–2.6% despite a challenging environment and a major funder under curatorship. Acute hospital PPDs declined, but complementary businesses grew 3.4%.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.